XLON
ANIC
Market cap71mUSD
Sep 11, Last price
4.90GBP
1D
-2.00%
1Q
-20.33%
Jan 2017
-8.84%
IPO
-44.94%
Name
Agronomics Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
61.40%
Rev. gr., 5y
-6.69%
Revenues
-12m
L+42.83%
Net income
-33m
L+198.00%
CFO
-1m
L-92.96%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Agronomics Limited functions as a dedicated investment firm, primarily allocating capital across various financial instruments, including funds, equities, and equity-linked products. Its portfolio spans both publicly traded and privately held companies. The firm exhibits a strong preference for pioneering sectors such as alternative proteins, with a specific focus on cellular agriculture, the rapidly expanding modern food industry, and the broad biopharmaceutical space. A key strategy involves building a comprehensive investment portfolio within biotechnology and biopharmaceutical companies. Additionally, Agronomics diversifies its investments by acquiring shares in collective investment schemes that offer biopharma exposure, as well as long-term equity anticipation securities linked to biopharma sector assets or indices. The company also invests in biopharma sector debt, ensuring such investments do not exceed 15% of its net asset value. Agronomics Limited was founded on May 3, 2011, and is headquartered in Ramsey, Isle of Man.
Related entities
Subsidiaries
Agronomics Investment Holdings Limited
Key people
Director · since 2012
Non-Executive Director · since 2019
Alexander Anderson Stuart Whamond
Non-Executive Director · since 2013
Richard Reed
Non-Executive Independent Chairman of the Board · since 2019
David Giampaolo
Non-Executive Independent Director · since 2019
Headquarters & legal address
1ST FLOOR, VIKING HOUSE
ST PAUL’S SQUARE
RAMSEY IM8 1GB
IM
ST PAUL’S SQUARE
RAMSEY IM8 1GB
IM
Previous name
PORT ERIN BIOPHARMA INVESTMENTS LIMITED
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||